0000950170-23-036789.txt : 20230802 0000950170-23-036789.hdr.sgml : 20230802 20230802081512 ACCESSION NUMBER: 0000950170-23-036789 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230728 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Talis Biomedical Corp CENTRAL INDEX KEY: 0001584751 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40047 FILM NUMBER: 231133802 BUSINESS ADDRESS: STREET 1: 1100 ISLAND DRIVE STREET 2: SUITE 101 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-433-3000 MAIL ADDRESS: STREET 1: 1100 ISLAND DRIVE STREET 2: SUITE 101 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: SlipChip Corp DATE OF NAME CHANGE: 20130820 8-K 1 tlis-20230728.htm 8-K 8-K
0001584751false00015847512023-07-282023-07-28

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 02, 2023 (July 28, 2023)

 

 

Talis Biomedical Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40047

46-3122255

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1100 Island Drive

Suite 101

 

Redwood City, California

 

94065

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 433-3000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TLIS

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors has appointed Andrew A. Lukowiak to serve as President and Chief Scientific Officer of Talis Biomedical Corporation (the "Company"), effective August 1, 2023 (the "CSO Start Date").

 

Prior to joining the Company, Dr. Lukowiak, 51, was the President, Chief Scientific Officer and board member of Epigenomics AG, a publicly traded molecular diagnostics company that developed the first FDA approved, blood based, colorectal, cancer screening test. From 2018 to 2021, Dr. Lukowiak was the Chief Executive Officer and board member of Millenium Health, a privately held clinical laboratory improvement amendments ("CLIA") laboratory specializing in clinical toxicology services. Prior to Millenium Health, Dr. Lukowiak was the Chief Operating Officer and Chief Executive Officer for Althea Dx, a private equity-backed CLIA laboratory providing proprietary, clinically-validated pharmacogenetic testing services from 2013 to 2018. Dr. Lukowiak earned Bachelor of Science in Biology from the Pennsylvania State University and a Ph.D. in Genetics from the University of Georgia.

In connection with Dr. Lukowiak’s appointment as President and Chief Scientific Officer, the Company entered into an offer letter with Dr. Lukowiak, on July 28, 2023, that governs the terms of his employment with the Company. Among other things, the offer letter provides for an annual base salary of $450,000 and, beginning in calendar year 2023, an annual target bonus equal to 50% of his earned eligible compensation. On the CSO Start Date, Dr. Lukowiak was granted (i) pursuant to the Company’s 2021 Equity Incentive Plan, an incentive stock option to purchase up to 13,477 shares of the Company’s Common Stock (“Common Stock”) at an exercise price of $7.42 per share, the closing sales price of the Common Stock on the CSO Start Date (the “Incentive Option”), and (ii) pursuant to the Talis Biomedical Corporation 2021 Inducement Plan, a nonqualified stock option to purchase 17,098 shares of Common Stock at an exercise price of $7.42 per share in accordance with Nasdaq Listing Rule 5635(c)(4) (together with the Incentive Option, the “Options”). Each Option will vest over a four-year period, with 25% of the shares subject to such Option vesting on the one-year anniversary of the CSO Start Date and the balance of the shares subject to such Option vesting in equal installments over the following 36 months.

 

Dr. Lukowiak will be eligible to participate in the Company’s Severance and Change in Control Plan (a copy of which is filed as Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-252360), filed with the Securities and Exchange Commission on February 8, 2021). Dr. Lukowiak will also enter into the Company’s standard form of indemnity agreement (a copy of which is filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-252360), filed with the Securities and Exchange Commission on January 22, 2021).

 

There is no arrangement or understanding between Dr. Lukowiak and any other person pursuant to which he was appointed as President and Chief Scientific Officer. Further, with regard to Dr. Lukowiak, there are no transactions since the beginning of the Company’s last fiscal year, or any currently proposed transaction, in which the Company is a participant that would require disclosure under Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission.

 

The foregoing description of Dr. Lukowiak’s offer letter is not complete and is qualified in its entirety by reference to the text of the offer letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

 

On August 2, 2023, the Company issued a press release announcing the appointment of Dr. Lukowiak. A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number

Exhibit Title

10.1

 

Offer Letter, dated July 27, 2023, by and between the Company and Andrew Lukowiak.

99.1

 

Press release dated August 2, 2023.

104

 

Cover Page Interactive Data File (Embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TALIS BIOMEDICAL CORPORATION

 

 

 

 

Date:

August 2, 2023

By:

/s/ Rebecca L. Markovich

 

 

 

Rebecca L. Markovich
Interim Chief Financial Officer

 

 EX-10.1 2 tlis-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

 

 

 

 

 

 

 

img150164034_0.jpg 

 

 

JULY 27, 2023

 

 

 

Dear Andrew,

 

It is with great enthusiasm that Talis Biomedical Corporation (“Talis” or the “Company”) is providing you an employment offer for the full-time position of President and Chief Scientific Officer, reporting to Robert Kelley, Chief Executive Officer.

 

We are pleased to offer you a base salary at the rate of $450,000.00 per year, which will be paid in accordance with the Company’s normal payroll practices. The target annual bonus for this position is 50% of your earned eligible compensation, beginning in calendar year 2023. All payments to you from the Company will be subject to standard payroll deductions and applicable withholdings. You must be employed through the date bonuses are paid to employees. Your primary work location shall be remote, provided, that, the Company reserves the right to require you to perform your duties at places other than your primary work location from time to time, and to require reasonable business travel.

 

As a material inducement to your acceptance of this offer of employment, subject to approval by the Board (or the Compensation Committee of the Board), following your start date with us, you will be granted (i) a nonqualified stock option to purchase a number of shares of common stock of the Company equal to 30,575 minus the number of shares granted pursuant to the ISO Award (as defined below), in both cases, with an exercise price equal to the closing price of common stock of the Company on the date of grant of each such award. Subject to your continued employment with the Company, the nonqualified stock option will vest over the four-year period following your employment start date as follows: twenty-five percent (25%) vesting on the twelve (12) month anniversary of your start date and the remainder vesting monthly over the following thirty-six (36) months. The Company understands that you would not accept employment with the Company but for the granting of these equity awards. These grants will be subject to the terms of a non-stockholder approved 2021 Inducement Plan, to be approved by the Board (or the Compensation Committee of the Board) pursuant to the “inducement exception” provided under Nasdaq Market Place Rule 5635(c)(4) and Nasdaq IM-5635-1. You will receive copies of the 2021 Inducement Plan and award agreements promptly after the Board’s (or the Compensation Committee’s) approval of these equity awards.

 

In addition, subject to approval by the Board (or the Compensation Committee of the Board), following your start date, you will be granted an incentive stock option to purchase a number of shares equal to the maximum number of shares eligible for incentive stock option treatment pursuant to applicable law, as determined on the date of grant (the “ISO Award”). Subject to your continued employment with the Company, the ISO Award will vest over the four-year period following your employment start date as follows: twenty-five percent (25%) vesting on the twelve (12) month anniversary of your start date and the remainder vesting monthly over the following thirty-six (36) months. The terms of the ISO Award will be subject to your grant agreement and the Company’s standard terms and conditions under the Company’s 2021 Equity Incentive Plan.

 

 

 

You will be eligible for Company benefits, which currently include medical, dental and vision insurance, as well as other Company benefits, for you and your eligible dependents, subject to plan terms and generally applicable Company policies. We also offer a 401(k) with a Company match as well as a Flexible Time Off (FTO) program and paid Company holidays.

 

You will be eligible to participate as a Tier 1 participant in the Talis Biomedical Corporation Severance and Change in Control Plan, pursuant to the terms and conditions of a participation agreement (if approved and executed by you and the Company) and other applicable plan documents. In the event the Company changes your compensation, benefits, position, duties or work location without your prior written agreement, you shall have the right to terminate your employment for “Good Reason” in which case you shall be entitled to all severance benefits without limitation under Section 3. Non-Change In Control Severance Benefits in the Participation Agreement of the Talis Biomedical Corporation Severance and Change in Control Plan.

 

In your role as an officer of the Company, you shall be covered under an Indemnification Agreement substantially identical to the Indemnification Agreement provided to the Company’s other officers and directors. In addition, you shall be covered under the Company’s director and officer liability insurance coverage.

 

Please note that your employment with the Company is for no specified period and constitutes “at-will” employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to terminate its employment relationship with you at any time, for any reason or for no reason.

 

Your acceptance of this offer and commencement of employment with the Company are contingent upon successfully passing a background check prior to your start date with us. Please refer to the Disclosure and Authorization Form below, which authorizes the Company to perform this background check.

 

As a Company employee, you will be expected to abide by Company rules and policies. You acknowledge that by reason of your employment by the Company, you will receive specialized training with respect to the Company and come into possession of, have knowledge of and contribute to confidential and proprietary information and may establish substantial goodwill on behalf of the Company. Accordingly, as a condition of and in consideration of your employment with the Company, and for other good and valuable consideration, including specialized training, access the Company’s confidential and proprietary information, and the eligibility for the equity grant above, the receipt and sufficiency of which is hereby acknowledged, you agree to sign and comply with the attached Employee Confidential Information and Inventions Assignment Agreement, which contains restrictive covenants and prohibits unauthorized use or disclosure of the Company’s confidential information and trade secrets, among other obligations. This offer will expire at 12:00 p.m. Pacific Time on July 28, 2023.

 

Prior to your first day of employment with us, you will be provided with additional information about our company policies, benefit programs, and general employment conditions. To fulfill federal identification requirements, you should bring I-9 documentation on your first day to support your identity and eligibility to work in the United States. You agree to assist as needed and to complete any documentation at the Company’s request to meet these conditions.

 

 

Page 2

 

 

 

We would be extremely pleased to have you join the Talis team! Should you accept our offer, and we sincerely hope you will, we would like your start date with Talis to be on or around August 1, 2023. If you have any questions, please do not hesitate to call me at 610.844.3950.

 

This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this offer letter agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this offer letter agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This letter may be delivered and

executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.

 

* * * * *

 

 

Page 3

 

 

 

 

 

 

 

We look forward to working with you and expect you will find your employment at Talis a rewarding and enjoyable experience.

 

Best Regards,

/s/ Matt Pepe

Matt Pepe

Vice President – Human Resources Talis Biomedical Corporation

 

 

Offer Letter Acceptance

 

 

I have read and accept this offer of employment:

 

/s/ Andrew A. Lukowiak 7/28/2023

Andrew A. Lukowiak Date

 

Page 4

 EX-99.1 3 tlis-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

 

REDWOOD CITY, Calif. – August 2, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.

Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platform engineering, operations, regulatory and clinical affairs functions for Talis Biomedical.

“We are thrilled to welcome Andrew to our leadership team as we continue to develop the Talis One® test menu and plan to initiate clinical studies to support our pursuit of multiple 510(k) clearances,” said Rob Kelley,” chief executive officer at Talis Biomedical. “Andrew’s executive experience and proven ability to bring clinical diagnostics to market, from concept to commercialization, will enhance the strong teams we have built during this pivotal period of execution to deliver a menu of women’s and sexual health tests at the point of care.”

Dr. Lukowiak joins Talis Biomedical from Epigenomics AG where he served as president and chief scientific officer and developed the next generation of its blood-based colorectal cancer screening test. Prior to this, he was the chief executive officer at Millenium Health, a leading national toxicology laboratory specializing in clinical testing to support physicians in their treatment of substance use disorder. He has also held senior leadership roles at a variety of molecular diagnostics companies including Althea Dx, Genmark Dx, Hologic and Third Wave Technologies. Throughout his career, Dr. Lukowiak has been responsible for the development of numerous in vitro diagnostic and laboratory developed tests in oncology, pharmacogenetics, inherited diseases and women’s health. Dr. Lukowiak holds a Bachelor of Science in Biology from Pennsylvania State University and a Ph.D. in Genetics from the University of Georgia.

“By having made such a significant upfront investment in building a cost-effective, uniquely differentiated platform, I believe Talis Bio is well positioned in the POC space with strong potential to decentralize the women’s and sexual health markets,” said Dr. Lukowiak. “I am excited to work with such a high-performing group of professionals and look forward to building out the Talis One test menu alongside the entire team.”

 

In connection with his appointment, the Company’s Board of Directors has granted an incentive stock option to Dr. Lukowiak pursuant to the Company’s 2021 Equity Incentive Plan to purchase up to 13,477 shares of the Company’s common stock at an exercise price of $7.42 per share (the “Incentive Stock Option”). As an inducement award to Dr. Lukowiak, the Company’s Board of Directors also has granted a nonqualified stock option to Dr. Lukowiak pursuant to the Company’s 2021 Inducement Plan to purchase up to 17,098 shares of the Company’s common stock at an exercise price of $7.42 per share as an inducement material to Dr. Lukowiak entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). All of the stock option awards granted to Dr. Lukowiak will be subject to vesting over four years, with 25% of the shares vesting on the one year anniversary of Dr. Lukowiak’s start date, and the remainder vesting monthly over the following thirty-six (36) months, subject to his continued employment and the terms and conditions of the stock option agreement.

 

About Talis Biomedical

Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The Company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “would,” “should,” “believe,” “expect,” “anticipate,” “could,” “estimate,” “continue,” “predict,” “potential,” “forecast,” “project,” “plan,” “intend” or similar expressions, or other words that convey uncertainty of future events or outcomes can be used to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the differentiation of our Talis One platform, the size and potential market opportunity for our products, and our ability to develop a test menu. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, the Company’s ability to attain regulatory approval for our products, launch and gain market acceptance for our products and to accurately forecast and meet customer demand, and attract and maintain our key employees and other risks and uncertainties that are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Talis Biomedical assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
 

 

Contact

Media & Investors
Emily Faucette
efaucette@talisbio.com
415-595-9407

 GRAPHIC 4 img150164034_0.jpg GRAPHIC begin 644 img150164034_0.jpg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end EX-101.LAB 5 tlis-20230728_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Entity Ex Transition Period Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type EX-101.SCH 6 tlis-20230728.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 7 tlis-20230728_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jul. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 28, 2023
Entity Registrant Name Talis Biomedical Corporation
Entity Central Index Key 0001584751
Entity Emerging Growth Company true
Securities Act File Number 001-40047
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-3122255
Entity Address, Address Line One 1100 Island Drive
Entity Address, Address Line Two Suite 101
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 433-3000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TLIS
Security Exchange Name NASDAQ
XML 9 tlis-20230728_htm.xml IDEA: XBRL DOCUMENT 0001584751 2023-07-28 2023-07-28 0001584751 false 8-K 2023-07-28 Talis Biomedical Corporation DE 001-40047 46-3122255 1100 Island Drive Suite 101 Redwood City CA 94065 (650) 433-3000 false false false false Common Stock, $0.0001 par value per share TLIS NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " #F00)799!YDAD! #/ P $P M @ 'J$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( T% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tlis-20230728.htm tlis-20230728.xsd tlis-20230728_lab.xml tlis-20230728_pre.xml tlis-ex10_1.htm tlis-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tlis-20230728.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tlis-20230728.htm" ] }, "labelLink": { "local": [ "tlis-20230728_lab.xml" ] }, "presentationLink": { "local": [ "tlis-20230728_pre.xml" ] }, "schema": { "local": [ "tlis-20230728.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tlis", "nsuri": "http://talisbio.com/20230728", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tlis-20230728.htm", "contextRef": "C_ddd315e4-9486-4c2c-813e-390a9110a98b", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tlis-20230728.htm", "contextRef": "C_ddd315e4-9486-4c2c-813e-390a9110a98b", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://talisbio.com/20230728/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000950170-23-036789-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-036789-xbrl.zip M4$L#!!0 ( .9! E? 8"2;.!D "($ 0 1 =&QI MZ<=1&$ORQ\>+$W*4\,E(QCFA9)CGXVZ[?7-STQ)!&&=)-,FAJ:S%DU&;4%K4 MW4LEP\?DB.62= W-,*GF4LVXU)RN871UO659'?O_-*VK:?.ODO$T#:^&.=GE M>P0_@I;C6$;1E'P*8Q;SD$5D4#6Y#WWD+7(81>0"O\K(ABU%"ZO\R[MA M#K0 >L39^YV%?M^8K22]:NN>Y[5OL1"&=E\:+A7- M5Q:UBZ+Y8M%PJ0.+I*XVN?9;/BM_?*+XT/WU9%P]N' MZM6Q&\AO9'=5/$[B4V![&O+5GXD\;>?3L6Q#01H7)6>]RL)5?8(1Z.T_/I\, M^%".&+T[="'O4#^3O'657+?A11OEH2J81^&7_O:N7?R)#T[^3R-F\7ZM#&6MMEM>_\1$Q)ED\C^7YGQ-*K M,.X2-LF3OX:C<9(" _.#,1.(,%WBCF\/=E2S(KRN/A)A-H[8% 5*PMMWX6T7 MZY9I\6,6:8F3>@DXQJUA/"IKW$& MO+0=E[N.!_4N]O00\%0@IGZ*V-4W]9 4@O-^!R2M&X2W4M" 10 ,']0_]WK= M7J9U*@.9@FF0V8=W"!+=3.DD]( HT.BB:K_?R8#)$2JH>C9,L8.H?;12M-9M M)H"G[>4ZBN86VU _LV22JE\*%+OEJ!4)G\J7\E.I.%W]"@7^#D*9$M4%N5)] M>_W?EOEZ]^,/U:/EVL= P$14OP"RTASMVH?"K'6HX5;?S=_-NBD>*%J]J7Y7 MC;272%/1<4:X]H+RM$''E*Z-*TWSDQ3>T#P9=XV688]S(I*)'TF27OEL5]O' M_^I[!U@S@"^.NZNUM+\?!- :S<+_RJX.O\?Y0:'GJJ+B@2H1L%$83;N7X4AF MRG6X2$8LK@K[29XGH[*\:@* ^2KN1C+(4>VS,8NKCMX,PUQ2>,)E=YQ*>I.R M\?U>+#;Z\Y^3)#^XTW3Q<)^ V0^#@Q%TXB84^1#4(:"/1'>KZ2206!^.NDZ:_G_8OCX_(X/+P\GCPSD_!9@R.>[]?]"_[QP-R>'I$ MCO_H_?/P])=CTCO[_+D_&/3/3HMR%2.^]_B-=8[_7X>#?_9/?[D\.]TG1ZU> M"]Q5V_(>DK%2)E 3NI82LN^@@B48S)ZAY!)PV$-Q!P[*CY7KO=B][5/?%1U[ MF^K[Z>SB,UFEB"]M<.5#T3-<4V\H/@%81&V>R MF\DQ2R&\*28#H/:TJOHZS$(_C""\ZE:ERT)02LRT?[%R#"]S4534SM.[-0X+ MDI?R8A9U$I85#)*F![ M2-XKF5@K*"]A+3PR/-?1%_X# ]P(G5@K@JN)9I#L"XES4F2W^BT91-,RRXF\ MQ@GL5+V68J]+#B=7$WBN&?O%5//N(^[0-W7W 7=(&IZ03D=2H#,#UX9)Z@G- MI([++6:QCN,SL2YWZ%Q-+!P7TPW+LT8"GM 1M#+$SZA@4SH%@E$9UUT1RKB05V&&::+\%-Y\?U3^ M-K(])#"7F*DC'\-D) 4Z3:27I&"/5?;KF>'NLZ3+K&U,UFG=G6Y^ ?EWCV\9 M^/\H8X6K5,D681D9C"7')(@@84SZ>49Z0P:>4KKW2A,.WQ8G-W;DK=B138Q' MC;OAZ(J0]=$23ZG$?;2(=;>A9T7&,%(D]OL=<^>M1LG/\!W6&OIQ5P\,KV-1 MR5R?6A[X#J[;":AIF;KOZKX1Z'P]OD,_YG/S.LA!^GO WCR=]A*Q' CB@A?, M7>=RG";76$_](\ C&;$;ELK'_8J56M:HP_=1!]?77NN1[4MVVR]7,7$%]]LAZ)9#3=TP#-M^AJ1_Q1'J;)$? M5$2&KZ\;M0MRE:>#R;"S?"A3\NLD#3,1JBQ9L?X(0M\EUVCE%&H=\;(1B0=$ MHI>,1F&&6R((>@&D0,>&[]O.]_[%@!R/QE$RE6FA^\M6DIPFK:\F4-"&U%8L MOIO[]&,GBVJMN@V/&AXU/&IXU/!H^WC4S,C78YK&[;@=0S=,RBTIJ<4\@S++ M\JAEZJ:P3=OBMK6>:9I#(5*99>4_)V$L];I/T#5S+%QW7%,ZZ)K;O2Y51=ZD:3*!UHFOZX M9S!J-##:F,>WQ=?7RF)XS'(TG8-1%#:UA,>H:SB"!H9AFZ9I=)@CUPID/?CS M++U,;FJ?@[Z0XB9)!,$1;?,BY/W'MA*N4QZ9;=F6PTSJF""4EB-,RCSI4 ,\ M-]<,?(VYYEKE4244SM+S-+D.U6$E6[YRH@<@ T.,0U:3_/(/1.+-6SOWPSE2 MD.K-FDO#EHYA"D%-2W2HA9:2!8Y#74N:GJLYTGSY3N#I/ '^B_P_':EE7 MS;''LS2G2?8W&;ZG9OA*'<#E[.;_?S3K:'I MWD%&+F4DQ\,DKE9DJ1-=HPFRFQP"7Q5<=+_7%$F,87WT:@3XGG,DGNQT!#=\ MJDO!J64RC;H=VZ4&XX%E&I[0[1S]XAFZ+Q,_WM, 1 M9H>ZKF#4\C2(@87.J'1-PY"2&5;GQ7N<3A( ]7,$CRU9ZVZ:U-0T[1N"W\9G MVAJ?J7&.ZA*:;I#R;4E\^ D,H$S)J3J>("7ESW*&9Y^$ 1Y)$%])00:8AR$G M+,O+\YY>[Y "\UN.^VU.*7@Y)>\=WK>*&C7TPWI#R;^H\_G8>)PFXS3$[4I^ M1Y@.C_O P@&JL7B:?4N +.5W.!WF,<,<:M,MC+PVD22 MDJ^9_44$P%L+#M;G!RQIKZK[19Z!\^BA#YY5P^,0JPIGTQU8Y8:E;%\I#M)U MX3O<\BF$W1+B(-VE3.]8E',N1>"XCB5?O++T7VF8@Q[@%K=)7.YKRNZO4?"3 M)/(9*'D.4%-_%/WY)Z]C60AKNK=TCOTP4Q3*T%!1_=#MC [,;!;. ZKL3S]X3%76HQJ5/7XA9E M-N_(P)5BT\2NP.^_2R;R+2!X :" M&PC^*@2#2EEX7_53(+@LVZR W-SCL;V-R:ZN.9";3WL5B2"92K$DSK.KI)1' M42:&0(2[-5A583Y^8O;C)W/K]AHJL>Y64@?7ZF["VI@EK#=_/4CM-+$XB>X2 M+V@O;JCB0\(CEF6;YF(\+!7%,@;#MO>K_V&#>YOF?VS(4J'-Y&&CV6L7@:7*-2=WAFBFHXPN76I[0J,\,B_* &[8P3+WC:B].'Q?1UU0W?.7XU7^B M!.<*0?@'><*_[)._0=V:IA.(Y<@UBR:2C"4(^K ^%[ T-F[3./)6\:C#'1Y( M85"?ZR:U=,VC7D>7U/:XIKG,9Z9\\0DBI:=:^*CU!Z/+D_Z@P9D&9QJ<>8[? M$S#.N>_0P' YX SWJ<=L!ST@2_.D;WJVO2Z_ITJ)J%ML[R42T9O^;F>GO384 M#24Y99E@?Q:^$?G,TB\R)R8DP_QCN'<:_-E'"U"0?&_06B M-ZGN";JS0R;,"(Q6 H>N<.T;C/4F'V(R<(R[9EA&A S"N+@MMUADK-E5SN3. M"F-XJGNF2781_CH'ZO@#(SA0"XZKCZ Y4) QWK>+>]^*S*+A4V-%G4OIQ:)R MZU[EF&V MNZ[YS#=MPPJT-1W<60WV%S767C'4M[%^Q7G"^I5&FUYL2X*O6(=]L DK34UX M;Q_F$ R)C"3/P9#$B4#(+569^#)U*!,JQ:BN:8N,W(32- MJAS#&.!-*J_##+X#\\1BCNNUP^E8PS!L6GY#!-T4Y@ MZ6Q5\=;FJD<- 1PG&CXF8,N7V8LN!2O8!L;],!8I5'O8(B>3+\E-R+ZHTR-D M>BTQB#U/918BV0G>W],;AC(@ Q[*XH[,BG'8P"70+B,?PV0DT;>)@/.S"W0) MV44_X>>?3.N@=+;5WWO[1 8!"A:T=CBYFF0YT?<)!*CFXA>#,S+(05+)$;A, MQ8?U"5+7$Z5N*>1O$#%JJ.#GX(>FJ*[_ 65&YQU5IE?%&$?I7*?WB0UZ=0,* MC45F2KW_L$:CNOL*/$823\]#%3\>AU P+!<(%YMGMR&./RKJ<)C/*<< M!CMC^OT>?F709Q 9,A7@+0[Z(8)@_'@(54I&CFX71D[DGQ,(ABCJ"C 0Q[,X MDB)B+,\(@D\D@#8(8C6@:$JO89R"H=T9#QGH!D] H"0(B6*EBC_+D9*@9*I9 M,!6I#J"G;50U7;0MLM3T 9%0A>A3W MG!8YBXLA+3FR*_#Z"N?\H)K=<&]IUFV!'G.^HJ$CQPJ0\51L9"! ^'G$8M7S M=FR$_,VDU4T MK**$HC=S*IRIPGX2%R52Y0-LQ[5V^MVOM 4W JBIU MF2G372:HOC#Z()FD5*E),=V\7[1C MV'^O&%<..9OX_P%\4@'E9%[A=6GJ2XXFL2QJ UU31K94UA7<1B[B8Q\T.I[+ MR=.: T(6FAO&>!]25,Y"7)>IW?D!AZ8#?FR<#[/Z!)F;:UF;&+/>;L:RC4(H M\.7,7\Y)Q<5CJ@.ID]Q/42$Z3 M%C%-DQJV83H:F(>BG1E<+JREP [/\EL(X&&6J6E0J%3ZZ03!JO!R]+T[$8JB M%HNRI/"?"N]I9<>KI)M**2$!4$I'L8I,KB#85<-X*GWT3:'/KRQ6Y#&,BCZ; MJYD-3-4;IB[!W9&H$3$$*/,L ^8RU+$+2L/0N/LROY$R7M94%?[C6)8B4R=:*Z5(%X,_7.@V1WFD!\9R-\DD$C .B#^@MP(: S\>4TG%*13Z$I-!/G3)T)*@QX->KQBI@Q,K[Q*4*V$S'@:CF?9SI6S M*DNS#PIW\F+)C2SC%'@VCQ%!L4((-A 54@E6'80^E5"!FJXLS362M5+IQ=KW MGV3NX6VOT.[RQH.967?I;TT@T^CX6]?QL[C*,!OS2!]I;8@68]W+B"0L'JH<$,6C>TM2UG5UA-?YGC='Z%;+,CN/ M'UUD/5+$M5H0$K[VZ47K/?E@?O#!ANVLJYW:5+A5W*?WPEUZK\3DFIQ0LGG, M)9O)STUC7&V55ITJ\9U.'MFJ#= U]'4Q+/RAZKQA+*S?'O;:DY^188H;;O(H MS*B\U;5_ZZUA/GJ1;J$U?X9VJ5X)R6P#M M\Z5YN@*TEV<*&Q1^.RBL:]9;1X$&A#>&_#54H)Y:47G.KG#5*?C!K-C==\1R M1M3BHMWCD2^%*-<3E4O&^C%B//GCX\4)$0F?X$3\TGJAYA:,&J8)?SPQ7GM/ M^7/)5MYROWU'( _ZOYP>7OY^<3SX(>)XGZY; J?G=_8KE"NN9EOHGW#TU_ZJ M0V4$3DMP-E%KP'#U2%JL&H%F?$DRH""\2(IE*[X+/%[B;CMU..E[P]R@^GFA#4<:CC0< MJ0U'K);Y+(X4Y;-(?D(_]L\_'1_W>X0GIG5V8 M^8TZ-AQI.-)PI.'(IG!DNT.DYSH;VSI3C%OZN]NCD U;"[8NYTX;_FX;?S]. MNW7<3K81TO>56QD;P7PIM]M9FUQ(7W+.R$E+7:N27(=\^/8\C&WV#1N.-!QI M.+*='.DT.5_L_THCIJX87N5X;? B^^QF]TP!Q;QKYQFF<,7H_( E?FNW/+\ ME&8AT"NN?7G7]A,Q_?"7=^UA/HH^_ ]02P,$% @ YD$"5P;C/& / P MG0D !$ !T;&ES+3(P,C,P-S(X+GAS9+U6WV_:,!!^WU]QR].JS4E(U:Z- M"E4W5@F)=A.TTMXFDQQ@S;$SVRGPW\].8AKZ@[6;-![ W'UWWW>^LY.S\W7! MX0Z59E+T@UX8!X BDSD3BWYP.R47T\^C47 ^>'/VEA 87HZNX1I7<)$9=H=# MIC,N=:40WDVO#N#[I\D8IMD2"PI#F54%"@,$EL:4:12M5JLPGS.A):^,I=-A M)HL("&F3?U9(G1V&U""D29PD'&(DLA O.8>*B-$Q0H[K#/&QRKG6> MZJ8&0]4"S34M4)'&BON3U 9I2]T"77=6ARU1W(N^7XV;3GHP9^+G#KHC+#Z,G'M& M-7IXIQWIDR,>(3?:6_9*>/J$W$N@0DA3\SJ3-Y8E$W/96*S-=2CU;9K@ M'.K!3:G*E.2X?[RC4LD2E6&HN\>Y3K!4..\'[FHA_A;YP>DLM&?'0QX1[,Z. M*B7?X;ZP>WN)V,]E_UUKJ60A:;1M?$?OWPCV;_>R'R+\)*VHSL)*FB MEA, L\^&E\.]1J\R1_ND9_6P]F+WL>\!G5>"[=(F@R8;=-*=10^3/$A?:#6N-OE?M@8T>G-C6T#G7C:6Y90:_ 5!+ M P04 " #F00)7ECS!K ,& !/-@ %0 '1L:7,M,C R,S W,CA?;&%B M+GAM;,U;;6_B.!#^WE\QQWWIZC:$4*EW16U7'&U7Z/JFPNI6=SJM0F+ VF C M)Q3X]V?G#9PX@4*=]%/39/+XF8D]'C^=7GY9S3QX1RFN?GO[=^:[4ZK=;6:W2^9G@R#>#4 M^03B+3XV(? BWO+A!?F(O2*W&6%ZW(.. ME[BQ\G''=Z9H9M]3)Z1WU=CR9S5B7I.RB=ENM<[,]*U""_&;D9@9XI9AM8TS MJ[GRW0;PKT'\<.P]!DG,5SG[Y5EH;5U<7)CAT]34QRI##FN9WQ_N!Z&?!O]" M 8\::ER? ,3AL$?($Y\60KP.HQXJH2@>F_' H7V _%""I/>7\_Y;;0*$'&1 M&PZ8#DD=R<@3X:7/*T#ABX',*X? ^ ASZO&7J^8NDG?$AZ]===U&?+]0<#7 MQA-[9O05BT^4)UQJKIWLD-DB>0S6LQ'U%.SDY]KI\%6/'1SP$1]X(!A/! I. M"J-J/VJ/7SZQ(5V27=]SRU([Q;\9#OBZ%+-_07"4^WP%0;5=11'L\37);*_/ MU^/J+[0NC%_6KB)Z0WO5=_G0>!P'YG$Q&RGS3+E]171?T 3[/$XD>+1GQ0H,)4.\FDWHG&NR6NJ&(4#-5VU2:<9\IW>.\? M/.]1=^<>(AM71)37:)3-*0L70;B+]>B"+^%U*>/RM[13%Q6B]SRE!!4N\YR) M=E)BR^CRRKH@<-)C[60RU=2;2J]*BZX>Y:>B[DAD.2=0A4UZKK^.0I6KM4>#<4AN&35IB:5 MU2I#CEA2HH2/93+"2(@)_$I(1(@8WP;R89['EBZ8\FBZZRS]PQNEY[.]% 8! MW;CFL(:SA0L1,$3($$)?FALR[^=0V5G[0&R7'"< QLL$& Z:>=%A..HWZY@ M P@1HA[^2HGA0/+IGW$B,.!HX=]G*DB6DO#P3ODRP@0."@)5IQ>E8L1Q[DC0 M6S5"/(!&U[+ZQ8%^A# 0XFA-0-OJQH%4PQU68&B,:K'2\5XEL?Y:6%)$#HVU MP(!_$Y3_--60"I7DT"HRAH($2_^NI!).CMR88DB(,"$&U>.%I+ 6X"8*1+YHF0.!54'$I!)EWVC_C"]'F@6"XI-5Z8>GPXHEH6K!97>?0 M8[5X%^@8K/;IZ!,DJ'I+1R']'%LQ"HQ2EETF2ULV_1L) _H&C2JOB57ARCZ-((D;.Y6I>EQ0MH[6^R'[LEIKJ<:BH(29AKU23ZJ&J:I-):.94I'HH[FZ>*2AB/T;YJFRI24.< M4X]JJOU*&FW2ZJ](/ZIUDREKO\GL,X424CT.*)MR$LIYO:C.*.=;=>309O2B M#[ +JAIXE)M@3BSZ6.2M?^V6X"R95TJ H44MZ4< M'NB?UR?)'1S]0]+U_U!+ P04 " #F00)75:)49;H$ "G+ %0 '1L M:7,M,C R,S W,CA?<')E+GAM;.V:77/B-A2&[_,K5/=F=UIC8[+Y8$)V*$EV MF.9K@)WN]&;'V (T*TL>203S[WMD4(I!)LV%W2ZZ.9N^(@>\0KU(T5> M\ V1$>5R*3#Z,'[XB+[]-KI']X3]F(82HQL>+1/,%'+10JFTZWFKU:H5SPB3 MG"X5#"A;$4\\Y+K;[@<"A_HXN@D51MW #SJN?^'ZP<0_ZP9!M]UNG5[ZG5]\ MO^O[.Z?Q="W(?*'0A^@CTF?!V(QA2M?HCK"0122D:&P&_14-6=1"?4K12)\E MT0A++%YPW-KT26$&76JFD4G2E=$")^$]CW)[/6=G/ME4T!87E:I M0G]SC77M[Z*I7$)H1N MV]ZWA_MQ/D\7KI ":MBY/D%H@T-PBD=XAO3[U]'PM1,54B*GA.=74J/WSX,+ M.)IQQI.UI^7>"%Z^FV@P[WT6WS)%U'K(9EPD.5APF0^V$'C6XYTB2I!0[WM^S205<<:9RK8[7K5R[K79F<%@/L3]^T2_.%&8QCG/\ MQC+E44%$=3!R442FK4OPGL>+Q%%KSE^\&)/+FT)SY6;Z,%2LA[NCX=SBIMA>&YMG+ B'^(KU M+?((I**N\+G6WKZO)WFV" MQ1R>NE\$7ZG%@"=IR,I-VM4U6;TC%#\NDRD6I?YV)#69@F@%NFK\EN/X[A\26W;_#XPNU2 MJS;MOV8S>(?-H&:; _CX)"9\Q=XRN:.LUV*^/)[$L^ O1">';_CC-S7T><%9^2W]0%*YJ3\$49 #PW,M M6;+M34Y:G-EUE=N#K22)B(+G[P/$N(#=I<6;152YL6>!-0O8P>,\4];;"/$T MFUDOZQ%QW4:'4BZQ>)?=PU/J2M2R":2NDNA8VV39Y5G:H;3ZV,31$E;%NAU, M)WJS:8O,?4GEI@"#KBB-U\F4V]9*L;TV1K=9M C9')?L5JRR@KG=?7Q?%(V& M(C)]PL=":>&PI+-5>&DHH#\W6A#Z&E8SP1/;?MR,QBW;8\0%K(N>2,^!%&@IP0A/M65]WX(IP.(1.+[?3+S48NXOI_/?9;"W:=]"^.0W"D)) MJ<# :#<*AKTP85@$#61Q4 Z8SA\:B"'-PI*!LU9 M ]&4%JP,E/,&0K&6Q0R0B_^!; IP!DBS\M+24M\6QUFS,M3C947#I(F)JKUZ M:8@T*UTMEDD-@V9EJ8?56<.A6:EI24'8P&A6?FHK/QL2S4I'C]6[#9%FY:)O M%]8-ER:FI+;:O>'1K(ST\&>"+8?S9J6B>[],& C-RCWMOX<8%M5EG5?> 0K8 M)OZX/MDVZ!?]1]?KOP!02P,$% @ YD$"5]=N>29W$0 2XH \ !T M;&ES+65X,3!?,2YH=&WM76USVS82_MS^"C2]=.P;2I9DV;%E-S-.FO;<:Y-, MG%ZOGVX@$I(0DP0#@);57W^["_!%+W;C5+8E1>VTB4006"QVGWTE=3JR2?S\ M:W8Z$CR"/]FIE386SU_]M]%N-=NG>^XC#-CS(T[[*IHP8R>Q^/Y)PO50ICW& M]-[+1!CV6HS9.Y7PM!C<5]:JQ(^G)7@L MAVE/R^'( @FG.$=!0I^'ET.M\C1JA"I6NJ>'?;[3"NC?W9.Y[]J[)^.1M*)A M,AZ*7J9%8ZQYYN@:"URBUU=Q5-]*>X[R[S[FRIZ\!+KZ6KH/ 3,\-0TCM!R< M)+"-L8SLJ#>0%@A++; (2']U/9)]:9D[#YSQ^>E>]IA,C<5@CJ>(%=O? MZL)R=*']1:C"L^:S_?T'T03_'3GMJ($'K>.G?\6P3W?FVYVCH/SO$USZ5.F$ MQ_/;G.?^F98\O@/O&6,___;+'ZSS+&"=5F=_\XS473FR[B9J51%J_\$YYBO*V M!'N(^9_]9=K#59#!<\ND86-I1VRH!;<,OA[E1G*3,#N"S^]AIX:]D"H1D0QY MS%XJG2G-K50IV_GNV^M.JQV>T"CW(3IA2L.]@A477ZHDX^FDN+R+*V9:74G, M4;*)RAE/F4BR6$T26)ZIP4!H-O"S#/(X;E@X+)8I(VE9-6!OM3 2CQ[NC=C+ MD10#=A%*^$(.9,C>#.#_0@=,"\R)XCI6P4'WA;;LWR*.Q23P=[VZ%F%NY94H M;FJNK7/Z0-[ 5A?O1Q=_%XQK$/-8<",B%%BG":0AK ]?PBPQUQ,&>HFJ 5HH M4!G^T3T ZEO IQ;+\ 8P+ &#G80C4.TX9GV8EGQBF-LCW#/1"F[/- \MJ(9ILO_R!"B^.,Y3A55.XE$E$>XJ*&D(-G60RPAA0A.T8J M1E""C?X!"R2YL3B?PR8\DA$(T] Q+4+FT^9!=.G3B%Q[(X TI N"^($HFR8@EOQB !J)S=3Y5B*8 L3XI\!<:FV&!@)HU)B M6!_L1"H,4*7YE8B7A9O=+6[>&VX>-SO=]H;!YAF(.4M &_$^P _0;T%^A(,) MC9 G,DN0!VA$*.6 %3Y5;D=0APV !5!'1+<)Z=P+A1BRXUV2ES7LP@^)M%;X MR?W8W0 @,8[5V+LX&I$(? ]"#0+>W 2DN05H#36''<$B'[Q MAIV-24JY 2LWD&AN^P)$$&01K"J P@A,*UBKP D@.MW70H<2! FL 6A'*1PX M81B#)0?A=9?^0JQ0+@N;")>(2%(O#BZ(R>%_'&EKLHM*QT@K<+=P7.@95 ' MK&/BC.'-*D$J!.81EKP2/FJ R1OD/X!9E"J:U<;::C7%Y,:/,SUFQW!QTAA@ M9 !SA#ATIW/P=)=6PHG\IF%@#&-VVIU=!@PBSJ9PES9H7PO_I[X*6M0167Z. MV*_+&>GV>%+?1D$UP)8&\$;ZH/(Z >=;C MX&V,!I-NR\"+#I'V26=M2#ZDG;BC=$L;/\PL\KV(.4(G!$H$:0TZ-G2R8'\. M8^$LP<-KL_,*M]_&'%Q"F "F*P=]-A#/:4H1EM8LA;A&SL D90A;>&..I^PU M-Q'_R'[E^E(0@: 2[W+P@0X.]P]VPMV=[BX=JQ]W_FL#+S3:SH\DWF@1"I2E M4&72X302LVCOSC$E7>80E OG] )%269!./C >NF@#59>^^U<*2);EE$9'PH&GU0PC\=\8AZWF78%.;8!G%@MW^ S M"Z,;[QS\4;/24^:S#%U$"D&O-47B.\RUAEL!R<' QGD$YMA5L *&)P%6&K'T M2AI*5JXSU@-@450#.NJWVSN6N#][+\0FW&%Y75'/V8RRN MB1R4'"QKL9T?W[_9Q1 "[$Y"-%"VNI@#(C(9 ;RML67X8LK07XQRH]Z OP;* MD'F_D(- @R:TJ^]AP])Y@+?6J2\$.'.4 ';58IX.!=[X$BC0*O89A]E$P4*/ MBU(9%5TX>^7%[9*RF,)89_;C'.)+P05^=A^D[U6:<,?^7EUY)5(O"@F\Y+T=NIP MS\K#];[]WQ:T;7IE]4%V(_L+SGWI%P31P2EVTE#+RTPZ/YC6PQ!#X3(5"G>= MPU^2%!MM9G4$?!X,6*TD[X8:=$A'BB+%C3>6^58_ES$&SZ5OZ.:"P/#Q2DLW-4#_)!1(+R^%X8X5 MLS5N>;K)[UO(D;7%HTUT^MY2GQ-6ID19K=*W5J>DZS-*%3.9"%TAT*<6O9=F MP&, ?\N4+@>'C8!C6;H;U?1-1HT#6I@\]MX-=O$, )%4HH<=1VZP6,6&B&^MBER+'/=]PTF0<=+9 T[VO\( TV.^3:>>UG.<046O[I M7)0?L:6.VBB*Q!+WUWT[7D%WK0./=C]+W#:WLOKJ>=3<;QUNF':2E2O;OWQO MZG354UR#.;4^T.Z#&X[IBK+W-(^%\[>KS"3F:X )J1I#>#[TYKM?6:;!G"WW MI=NI &.J+8(L.O#\3R1#A MJ.C#I(US$*R6_=R2*89/ Q>A^%PPQ" (,)BR5"FJ,D^OP/7$@[, T#I0_ _ MJH$X<8L#I(^E5M!F>-RB3P7 M0Q4]1;[/Q%<_^Q!/!;X,"U*0N3*HR3$$DV OJ'+K0!< %;8H0(QJ'H.5VM)N0# *)@@X$E6&9UID;F#[K%#" MR8&N&A%J@8D^GBBLB+M &01UZ!Q*K$^7UI@D%?0=6[E!9]N='CXST$S ,O*0 M'IVAF@$L\',.'.P5,U,4*_=U9>OJ@.@:@H?6!L@#0,1T4BGOF7.RS]( MD;@BH.R]2_MP3I[.X1ZO(,'VQS5]P*UMG$.NS"0,KT^\SV M;ZE$*W\!$Y=6O,!.=*IA>K!.J1"1+U^0E82-"NJ8FF,/[8,_CYGSO MC*4M8W,D/XN_&,XE&RQZ/UA(K-Z MT)OR%>@+?E!3_2Q6\.0;=N$<1(IUW3,\Z/510.>,VM'B!VY<88&[Q.59/L1'H-L^"&3GE)1PU*(_2'X>NG2!WPQX MB/2H$7A\V(_A\BQ8B4THW#R$TSWJ=IO[QP>M;4BY^B'E?R@PJQJXGC5LHJ&G=Z@;,'#3%Y/4W_% CU["LJ&M'=8G4U9D4ZL; M8,4"=ZLV%\W@$"0I&F0KO\L+%3:>B+))QO]-C!KWL>NZ%BZ+AS8S3W"W;9Q?@'>E2VH M5Y*S 0\-]BB $(L8)%*K5(9P3#)F.U5U((L&S/<:U$:AXG&;:X]HD[) 0ZFE MYD6SS'B]NCC_Z34["TF*.JU6*\#4$Y5&7U7SO== //?O8J'!>KX5%D1JM[I@ M\1: -=*#! #,%SQ*-8A0:RJ/JB\ /2),9/NRB(S@[U/B6+7HX@>8PBD]72&E M1:RFS@M\ TVN0?K%\IZ0_2*<%WJ1Z,.\RG?V!:;=HVEU?LP\SK(8_T_F_UV- MU^U; FXLM,1*76+ 3J]?\0TP9:JB> ;7=;Q6_4(#63[*7TO"%F^_QJ=$ M<#KJ.L>[TP]J0ND)G$=CJZ)8XZ:6S@:7,S9*NE]@5]4[,<27M"WK%P/NX6F? M%>,:F_EG=1FW7M(XR]^Q7;BU[ M*S)Q?S"W_\7_,,H#,/EO)Y\;:ACXQ57:S\K' M;[?ZM_;ZMPW'UL):GKLF RVXZQ?PO9DW_>.1W'P6>]=F2Z5 M'X/;V?F$4OGGUG7O3WC;S>[AH_U.\/H*[WH$;LO:*X9N[I<6V5F3_9)?JK'D MEQOP&R$+@_"-/LQG>YVCO27^:.]GA=M_!9Z/_4/)]RI>\XKTU5=?E5=_X'9% M?-!M*\ZV%6<]MM']K%:#DY7S$N:'1M[5MM;]PV$OY\_16\]!K8 MP.[&:R=Q[76#' P&A\]B#_QP(/F MB:.I35?"AU6AOKM72C?3YE#(.MA_ZK*R+D@3)I5,4VUFA^+;:CFYQ]M6[9*@ MEF&H3:I,.-P9[7PSR:P)0Z]_4X=C_*[")&XZ#+8ZC!?XB4R6NE@=OM6E\N)G MM1"O;2E-^_#4AF#+YGE^A2STS!PZ/; MRJV= ?^W/=FX-MZ>+'(=U-!7,E&'E5/#A9-5E&NAZ!6'4UNDFT?I2W[_0VW# MY)+\\>) >.5T-BEQDH5.0WZ8Z0#93("6(/WS9:ZG.HAH$MKTR=&#ZJ_4:X+7 M*/=7*/;A32KV+4[CQ5-M2Y7J1!;BV!B(GV"G8Y,Z;/:R/K<++<\'XE4^>C8: M".G%*Z>\)D4+:5)QDFN5B3>)Q@6=Z42<9?B_Q-Q7,]J'\3N0.SN[.ZMKV]$ MY8EU2"TR:&O$UL_2I_+#H7C[\O3--N)1I%K.C/4!H9?8LI)F)5)>&%0J@A4R MG4N3(!\)I+ BY$)]J'58*[<2-A,R26J\60EM M,I5 @MKCA5Y)KT10>"FVU8:7E=@(UL(BHU0*R0)?KJR.5Q/IE-AZ=78"J8-- M)4D0T09BYG@:")\#7F3%2W#UF1NU.'0\ZJ"((*BZ $$)0Y!?0Y"-$#00*F.I MYZI5]C@J>W0C;O[XSLW9S%$EES%(H VD%Z+RGRYJJP%47"0%2%#'BL%,K "Q2. M:F8#87%FCF4_P(:S&@]9%\.Q.[W,,JFAM0SAP8_RZRX#PYT7WZ071_Q-)N]@ M2W9?!ZM'"%VH@F"R!2-M/M2IIB1J!=1+52#[1U4[CTQ+$%/61= 54./1>&?K?!M+ 8J2B/8@NETZ M 473*<2;BA\5_&ZUOA'3VQJAFNQ&:+B!"*+UXNBJ\=?!Q/>6]T WXJ:=*R/D M5!?$"G"&*>'4U4B,NP"#3'+:E/372&]-C"KF)XSAL UN+XAZ MK,]*Q_)J66.+AO*0)?V5C&34JOG&*I7;]LH[T+\MZO(>CN$WZ3=[^O-*SY2Q M)47!\0NQR!5R!+FT8^"K0Y640V+RA!>29&MXZ+:Q-AU,P M;6(S4!V8+*1)*)H<=G8*?(JCR8<1BG+B5H@.BJ!(6J2/E.IZ^/B),IS1=2E^ MX#BAF!8Y2NO\;3Q M#H+ZY!91P)BQ9*@\#;2NDT.Z6RA.+2EF$O@ M6N"ZI<35!-3*78"OC@-"CJ2H^9S'.+>2XMER(%XH0^C&?_^!3@RSD;G>YMJE MXAV!U5N5Y(9O$9%\&ZLF5%&"<(OPA*J.#3X\A:DVR&,LM3JZR(53#0BE$@MJ MFFN 9;^X(TEZ!NCY$(,;E@",V4Y@GKE$V"26O(I./L!M>*RFJJHIWR),7D+. M")=0_,4CV"(EROQ4)C""9=+,#9_(VQ$J[!T<)Z^4,7Y5H.344KP)E"?_8PBN M?5MSRMA*HI4O&O'B4E)([UF\Y(6R "%YQW-O@^<^75'^I1 H$4R(P22';3Q. M2G@E<<:Z@EWPIS9SN!@[*8Q&^9HC1R*>?!AV-?9 U$9_J*D$2S4N.H(^[D*T MA=! G"(6"JWF:@VS0A,7 %.H+.P.S,&"IAI\=78B6%&@$LCB#7VH;."=BT@& MJ!?K"(DBQ_A=+A )S&7BU7=X^'^KI%,!8J^6B6Z:*0L+?(C"1'WE,-D01(6. M1THA9ZC(=\&K,N4]8V@4 WA^3I&_D([WZA1)^'&A1.@SSP)'IKP2RU2R6,B5_PPG$K_7Y+S1:<(-]CGO("6J M]-10)6"X06AB>% ^;#IYL1E"[GL2^Y/KZ'QJ*180+<\TT1OK/.?+&6JCP'T= M2M3D]',J'FQR+FS5E@$74A376H19S("N>-/NSNY8/(^=S]-NSU=-38?E24X] M3<0N?H[W!@_W]X5'%E6^;1%M;$D5#T2)),S/EP;V-O (6I5&6Z )8H!6+;HT3_^IVLW,JF^BH6Q MYD--K6F-GS>@Y-.UL->I=W^P<_#MK:A77M97B03DFEQQX3 \P8OD%;=4615V MQ2O8?7L243*220)*R@R5;\C^O.'3EDK>C/H*W% =1$%V'WW3O2>JLWL^IE"D4UY MS7:F5C(V]ONO7>L<+!Q\/87.!IRR: >G2DF Z+JM89:0(\NS2/1(9HL".\7Z MW845,&8IMO8>;\='(6SO0,R4FR99VE=\^T+8I8P9$X^E.O8_KU3F#'R;EMX, M0;R;WWUQ\[O+4^$;S6K'4R)FE]L!?R\%WS)QV.BUX-=G.[RD>G^=%:@=[/M- M_@A8ZR8HO=;8N>3\CFH *0EE.F"+FCM> O<4?&&(71;*W8T'OCC?%7[E@RK) M!921U-5I_6V 4F_!Q7',HA ,%>:Z)=7XWDA\;UV^^/L-9RA?C"S<$ MB'$]B7FH":62Z],[3_-0E7A4$07GW5*NF/VCI&A[8<.B<1_?N0\7-VUJ5I+G M',C"E']?Q>\\Q!N J4-Q #E?XH]9G)V\5OS!Q7'"67M\=77V\:GYLW:"";7/%6E(@ZT14EE(U[ MR=7OH,127K,@5ER;=V ?$*XKWM_U63=O932-DOZJ1@T_1)*$5ESLGZ)\I)D#?,%1_S7U\7,QG&BN5H(^('/D3G%DD-6A1D*% MHLF-:%W+$A-IJ+2N?626/*K3V8I\S*N/^"*GZ>O\-,Z15/^24S,\'/NZ3O ! MFZ]]V ,R_*514G.V.M#&1!5DL:+!#*2&;U/[7$3?B)\+Q6F[,_P5D2RI%1Z5 M0J$R\[$)U.^\-\-$$F/=6E[WXKF>)I[*GP%T3?78'T>-3;.[VA#;SEB/KF.Q M@X9_N_YG QT/7G>O1X)"UE]0#W5IC UB5DMN@L0.4&.VII$NVX\3Z.%>ZZ"Q MM'#:G_M!S_2Z&6=%?60R-KL:-ZGI,%H_EK>G8]AJG%]+6YXC'V-!1%PS"]N+?%TW&!B(;I\HG3D]5&NEP5I/Z M&_QOH>(U-A'?1].N9S=-SYE-67@5Y_*-.!E4B82$,2,/HC%8C'"6T8S.Q_TQL;-*XZ-(8]ZK>)7/X:PHA3CG>&/O-,O M<'*X$PX3G_#]1WX971T=<>1?5U0JKNN"GE0P&BI9V37%J%\7_WXYW49[@1A@ MU4)ULS=VV?[>]#>:\#HLLK&8@10Z?G;(3Z]E'&PNIZ0.:"T W104EF"/9NV% M:AN)I*O>,6..9!S@SRIEA.0FK*)?M-\'41,0_AK' 6J9(Y*YI-;F0ZW=BONW MG"&DX9!O(BS6.(HJM&"[M3E\UKSX&&>WY2WG>?!E+TY3F:VEN5/A*R7,X M$YWMD_U@H]LBO:\I-1HK[+1H.10=H>*]/D;0'-D4$L! A0#% @ YD$"5Y8\P:P#!@ 3S8 M !4 ( !I1P '1L:7,M,C R,S W,CA?;&%B+GAM;%!+ 0(4 M Q0 ( .9! E=5HE1EN@0 *#$P7S$N:'1M4$L! A0#% @ MYD$"5]-1"]7@#0 \CL \ ( !;#D '1L:7,M97@Y.5\Q :+FAT;5!+!08 !@ & 'X! !Y1P ! end